Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

840 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial.
Huppert LA, Wolf D, Yau C, Brown-Swigart L, Hirst GL, Isaacs C, Pusztai L, Pohlmann PR, DeMichele A, Shatsky R, Yee D, Thomas A, Nanda R, Perlmutter J, Heditsian D, Hylton N, Symmans F, Van't Veer LJ, Esserman L, Rugo HS. Huppert LA, et al. Among authors: yee d. Ann Oncol. 2024 Oct 28:S0923-7534(24)04070-5. doi: 10.1016/j.annonc.2024.10.018. Online ahead of print. Ann Oncol. 2024. PMID: 39477071
Adaptive Randomization of Neratinib in Early Breast Cancer.
Park JW, Liu MC, Yee D, Yau C, van 't Veer LJ, Symmans WF, Paoloni M, Perlmutter J, Hylton NM, Hogarth M, DeMichele A, Buxton MB, Chien AJ, Wallace AM, Boughey JC, Haddad TC, Chui SY, Kemmer KA, Kaplan HG, Isaacs C, Nanda R, Tripathy D, Albain KS, Edmiston KK, Elias AD, Northfelt DW, Pusztai L, Moulder SL, Lang JE, Viscusi RK, Euhus DM, Haley BB, Khan QJ, Wood WC, Melisko M, Schwab R, Helsten T, Lyandres J, Davis SE, Hirst GL, Sanil A, Esserman LJ, Berry DA; I-SPY 2 Investigators. Park JW, et al. Among authors: yee d. N Engl J Med. 2016 Jul 7;375(1):11-22. doi: 10.1056/NEJMoa1513750. N Engl J Med. 2016. PMID: 27406346 Free PMC article. Clinical Trial.
Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
Boughey JC, Alvarado MD, Lancaster RB, Fraser Symmans W, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; and I-SPY 2 Investigators. Boughey JC, et al. NPJ Breast Cancer. 2018 Aug 17;4:26. doi: 10.1038/s41523-018-0074-6. eCollection 2018. NPJ Breast Cancer. 2018. PMID: 30131975 Free PMC article. Review.
Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
Boughey JC, Alvarado MD, Lancaster RB, Symmans WF, Mukhtar R, Wong JM, Ewing CA, Potter DA, Tuttle TM, Hieken TJ, Carter JM, Jakub JW, Kaplan HG, Buchanan CL, Jaskowiak NT, Sattar HA, Mueller J, Nanda R, Isaacs CJ, Pohlmann PR, Lynce F, Tousimis EA, Zeck JC, Lee MC, Lang JE, Mhawech-Fauceglia P, Rao R, Taback B, Goodellas C, Chen M, Kalinsky KM, Hibshoosh H, Killelea B, Sanft T, Hirst GL, Asare S, Matthews JB, Perlmutter J, Esserman LJ; I-SPY2 Investigators. Boughey JC, et al. NPJ Breast Cancer. 2019 Jan 2;5:2. doi: 10.1038/s41523-018-0096-0. eCollection 2019. NPJ Breast Cancer. 2019. PMID: 30675512 Free PMC article.
Impact of Body Mass Index on Pathological Response after Neoadjuvant Chemotherapy: Results from the I-SPY 2 trial.
Wang H, Yee D, Potter D, Jewett P, Yau C, Beckwith H, Watson A, O'Grady N, Wilson A, Brain S, Pohlmann P, Blaes A. Wang H, et al. Among authors: yee d. Res Sq [Preprint]. 2023 May 31:rs.3.rs-2588168. doi: 10.21203/rs.3.rs-2588168/v1. Res Sq. 2023. Update in: Breast Cancer Res Treat. 2024 Apr;204(3):589-597. doi: 10.1007/s10549-023-07214-5 PMID: 37397981 Free PMC article. Updated. Preprint.
Multi-platform biomarkers of response to an immune checkpoint inhibitor in the neoadjuvant I-SPY 2 trial for early-stage breast cancer.
Campbell MJ, Wolf DM, Yau C, Brown-Swigart L, Wulfkuhle J, Gallagher IR, Zhu Z, Bolen J, Vandenberg S, Hoyt C, Mori H, Borowsky A, Sit L, Perlmutter J, Asare SM; I-SPY2 Investigators; Nanda R, Liu MC, Yee D, DeMichele AM, Hylton NM, Pusztai L, Berry DA, Hirst GL, Petricoin EF, Veer LV, Esserman L. Campbell MJ, et al. Among authors: yee d. Cell Rep Med. 2024 Nov 19;5(11):101799. doi: 10.1016/j.xcrm.2024.101799. Epub 2024 Nov 6. Cell Rep Med. 2024. PMID: 39510069 Free PMC article.
Gender differences in pain interference with daily activities and functional impairment among patients with hidradenitis suppurativa: A population-based study in the United States.
Kingston P, Peterson H, Lee K, Huang MY, Yee D, Korouri E, Armstrong AW. Kingston P, et al. Among authors: yee d. J Eur Acad Dermatol Venereol. 2025 Jan 7. doi: 10.1111/jdv.20518. Online ahead of print. J Eur Acad Dermatol Venereol. 2025. PMID: 39775852 No abstract available.
840 results